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Apoptosis, or programmed cell death, is a complex, genetically-determined process involved in the development and mainte-
nance of homeostasis in multicellular organisms. Dysregulation of apoptosis has been implicated in a number of diseases, in-
cluding cancer and autoimmune disease. Thus, the investigation of apoptotic regulation has evoked considerable interest. Many 
apoptotic proteins have been shown to be post-translationally modulated, such as by protein cleavage, translocation, pro-
tein-protein interaction, and various post-translational modifications, which fall precisely within the range of proteomic analy-
sis. Recently, contemporary proteomic technologies have achieved significant advances and have accelerated research in func-
tional and chemical proteomics, which have been applied to the field of apoptosis research and have the potential to be a driv-
ing force for the field. This review highlights some of the major achievements in the application of proteomics in apoptosis re-
search and discusses new directions and challenges for the near future. 
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Most scientific advances benefit from the cross-talk among 
different strands of research and are fueled by new tech-
nologies. Our knowledge of apoptosis, one of the hottest 
areas in biomedical research, is also the outcome of interac-
tions among many disciplines. Apoptosis is a geneti-
cally-determined cell suicide program that removes un-
wanted, redundant, or damaged cells, and it is required for 
the maintenance of tissue homeostasis in multicellular or-
ganisms [1]. Defects in the apoptotic program have been 
associated with many diseases, such as cancer, autoimmu-
nity, and cardiac hypertrophy, whereas accelerated cell death 
is evident in degenerative diseases, immunodeficiency, and 
infertility [2]. Apoptosis is currently one of the most ad-
vanced fields of biological research, particularly regarding 
hypotheses and strategies linking molecular mechanisms to 
disease phenotype. However, since apoptosis research be-
gan, many different research strategies and technologies 
from other subject areas have contributed to its development 
and have coalesced to deliver the present advanced knowl-
edge of apoptosis. 
Prior to the late 1960s, research on cell death was mainly 
descriptive analyses of observations. With the development 
of light and electron microscopy, some features of cell death, 
such as DNA breakage, cell shrinkage, chromatin condensa-
tion, break-up of the cell and its engulfment, were recog-
nized as being distinct from cell necrosis [1,3], and the term 
“apoptosis” was coined in 1972 by Kerr et al. [4]. In 1977, a 
cell lineage study based on the model organism Caenor-
habditis elegans demonstrated that 131 out of the 1090 so-
matic cells were fated to undergo apoptosis during the de-
velopment of C. elegans [5,6], paving the way for a genetic 
characterization of apoptosis. The central genetic compo-
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nents of the apoptosis machinery in C. elegans were re-
vealed in the 1980s and 1990s, inspiring the discovery of 
their homologous proteins in humans in the 1990s [7]. In 
the early 1980s, research on gene translocations and onco-
genic fusion proteins in leukemogenesis had become a very 
hot field and significant contributions were made to the in-
vestigation of apoptosis. Notably, Bcl-2 was cloned from 
follicular lymphoma [8]. Initially, it was assumed to be 
similar to other oncogenes, such as Abl and c-Myc, but it 
was finally found to cause cancer by preventing apoptosis 
rather than stimulating proliferation. Bcl-2 became the first 
identified component in apoptosis. Subsequently, other 
family members of Bcl-2 were identified and the Bcl-2 fam-
ily is now known as one of the most important regulators of 
apoptosis [9]. The identification of components in the mi-
tochondrial pathway is mainly based on biochemical sepa-
ration strategies by the group of Wang [10]. The extrinsic 
apoptotic pathway was revealed by analysis of the Fas re-
lated protein complex [7,11,12], while the link between 
apoptosis and immunological CTL killing led to the identi-
fication of granzyme B, a serine protease with a similar 
substrate specificity to the caspases, and revealed a type of 
non-cell autonomous apoptosis [3,13,14]. Examining the 
history of apoptosis research, it is clear that its development 
was fueled by various technologies and subjects, including 
microscopy, biochemistry, molecular biology, model or-
ganisms, as well as genetics, cancer biology, and immunol-
ogy. Therefore, the role of proteomics in apoptosis research 
needs consideration.  
Apoptosis, a basic activity in cell biology, is under com- 
plicated and dedicated regulation [15]. In fact, an ever in- 
creasing number of genes are being revealed as involved in  
apoptotic events. In the pre-genomics era, genes/proteins  
would usually be selected manually to investigate their re- 
spective roles in a given apoptotic process. However, analy- 
sis using post-genomics tools might reveal sets of genes/      
proteins that are up- or downregulated in a certain apoptotic 
event, allowing easier identification of novel molecules in-
volved in the process. Microarray analysis of the genomic 
response to apoptosis induction is now well-established for 
gene screening; alterations in mRNA have been exhaus-
tively described and many new genes were identified to be 
involved in apoptosis [16,17]. However, during cytotoxic 
stress after anticancer treatment, for example, protein trans-
lation is suppressed and post-translational modifications 
make the analysis of gene products even more complicated. 
It is unclear to what extent the genomic response is trans-
lated into alterations at protein levels [18]. The recent pro-
gress in proteomic technology, instrumentation for parallel 
quantitative proteome analysis of all proteins expressed 
from a genome, and for the identification of post-transla-     
tional modifications has triggered a surge of chemical and 
functional proteomics studies dissecting the molecular 
mechanisms that regulate the apoptotic signal transduction 
pathways [19–23]. Despite the challenges of sensitivity and 
dynamic range, tremendous progress has been made in the 
field. This review summarizes the main progress in this 
field, including chemical compound-induced apoptosis, the 
proteomic investigation of apoptosis regulation, and caspase 
substrate identification. We also discuss the main challenges 
in this field and some possible future directions.    
1  Chemical compound-induced apoptosis 
Many small chemical compounds, including chemothera-
peutic agents and some pollutants, are known to induce 
apoptosis. It is believed these chemical compounds induce 
mitochondria to undergo outer membrane permeabilization 
and to release cytochrome C. The latter facilitates the inter-
action of Apaf-1 with upstream caspase-9 and initiates a 
downstream caspase cascade, especially the activation of 
caspase-3, eventually leading to apoptosis [24]. However, 
the initial signaling triggering apoptosis, as well as the cel-
lular context, may vary significantly, thus the mechanisms 
and signaling pathways usually demonstrate apoptotic stim-
uli and cellular context specificities [24]. Determining the 
detailed molecular pathways by which chemical compounds 
induce apoptosis will provide valuable information for the 
further development of novel drug leads and toxicity eval-
uations. Proteomic approaches, combined with other 
biochemical methods, can reconstruct regulatory networks, 
signaling cascades, and metabolic pathways upon chemical 
stimulus, which demonstrates the value of proteomic plat-
forms for identifying drug targets, understanding the exact 
mechanisms behind the induction of cell death in response 
to these agents, and in the evaluations of toxicity and side 
effects of these compounds [20,23,25].  
Apoptotic impotence is frequently involved in carcino- 
genesis and resistance to cancer treatment, and thus induc- 
ing apoptosis is one of the main strategies used for cancer  
chemotherapy [2,26]. However, the network of apoptosis  
regulation is highly complex and one single drug usually  
does not work well. The development of novel anticancer  
chemotherapeutic drugs whose mechanisms of action are  
different from established drugs is needed for the treatment  
of cancer, particularly in those patients showing resistance  
to standard treatment [27,28]. However, the development of  
therapeutics from inception to marketing is a costly and  
time-consuming path with high attrition rates. The identifi- 
cation of drug targets involved in compound-induced apop- 
tosis is an important factor for rational application and a  
major rate-limiting step in anticancer drug development, for  
which proteomic analysis may provide valuable information.  
For example, arsenic trioxide exerts its therapeutic effect for  
patients relapsed after ATRA treatment by promoting cell  
differentiation and apoptosis [29], but the drug target invo- 
lved is not clear. Very recently, Zhang et al. [30] used  
biotin-linked arsenic trioxide to purify interacting proteins;  
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they found that arsenic binds directly to the cysteine resi- 
dues in the zinc finger motifs located within the RBCC do- 
main of PML-RARalpha and PML. Arsenic binding induces  
PML oligomerization, which increases its interaction with  
the small ubiquitin-like protein modifier (SUMO)-conju-       
gating enzyme UBC9, resulting in enhanced SUMOylation  
and degradation. Arsenic and ATRA bind to PML at differ- 
ent sites and this information could be useful for their ra- 
tional application. Another example is Ganoderic acid D  
(GAD), one of the major components in Ganoderma triter- 
penes, which can inhibit the growth of numerous cancer cell  
lines and were thought to be the basis of their anticancer  
effects [31]. Yue et al. [31] used two-dimensional gel  
electrophoresis to analyze the proteins with changes in  
expression level after GAD treatment, and 21 proteins,  
including 14-3-3, were identified. Furthermore, GAD was  
found to possess the ability to bind six isoforms of the  
14-3-3 protein family and other proteins by the drug target  
searching program analysis. The direct binding affinity of  
GAD towards 14-3-3 zeta was confirmed in vitro using sur- 
face plasmon resonance biosensor analysis. In addition, 14  
of the 21 proteins whose expression changed in the pro- 
teomics analysis were closely related in a protein-protein  
interaction network identified in the intensive study. In this  
way, the possible network associated with GAD target-re- 
lated proteins was constructed [32]. 
Meanwhile, the prompt and accurate interpretation of the 
molecular mechanisms for a potential drug function will 
accelerate the process and significantly decrease the cost 
involved in drug development. Proteomics was found to be 
very useful in uncovering the mechanisms of novel reagents. 
For example, gold(III) complexes have the potential to be-
come a new class of anticancer drugs with higher cytotoxic-
ity and fewer side effects than existing metal anticancer drugs, 
such as cisplatin [33], and their mechanism of action has been 
eagerly sought. Wang et al. [34] performed functional pro-
teomic studies on the apoptotic HONE1 cells induced by 
gold(III) porphyrin 1a and revealed alterations in the levels 
of proteins involved in cellular redox balance. Further study 
showed that ROS played a part in gold(III) porphyrin 
1a-induced apoptosis by regulating DeltaPsi(m). These re-
sults from proteomics analysis support a role for gold(III) 
porphyrin 1a as a promising novel anticancer drug directed 
toward the mitochondria. Proteomics has a limitation for 
detection and sensitivity for low abundance proteins, and 
can only reveal the most significant changes in high abun-
dance proteins, which may demonstrate only some of the 
important parts of the drug effects. 
Drug resistance is one of the major problems for suc- 
cessful chemotherapy for cancer and other diseases. Many  
molecular mechanisms have been revealed to be responsible  
for drug resistance, whereas others will surely be discovered.  
Drug resistance might be the result of the activation of  
different mechanisms and determining the exact mechanism  
activated in a particular case is a difficult task [35]. Pro- 
teomics could be applied to the investigation of the drug  
resistance mechanisms through the identification of entire  
sets of proteins that are up- or downregulated in chemore- 
sistant cell lines compared with their parental lines. For  
example, the therapeutic mainstay against the protozoan  
parasite Leishmania is still based on the antiquated penta- 
valent antimonials (Sb(V)), which induce apoptosis in the  
parasite, but resistance is increasing in several parts of the  
world [36]. To reveal the mechanism of this resistance,  
Vergnes et al. [37] performed a comparative analysis of a  
genetically related pair of Sb(V)-sensitive and -resistant  
Leishmania donovani strains isolated from kala-azar pa- 
tients. They identified that heat shock protein HSP83 and  
the small kinetoplastid calpain-related protein (SKCRP14.1)  
were differentially expressed. They found that HSP83 in- 
creased drug resistance and reduced drug-mediated pro- 
grammed cell death (PCD) activation by interfering with the  
mitochondrial membrane potential, whereas SKCRP14.1  
promoted antimonial-induced PCD but protected against  
miltefosine-induced PCD. 
On the other hand, drugs can have side effects. Under- 
standing the molecular mechanisms involved in the side  
effects will aid the reasonable application of the drug and  
help develop methods for avoiding its side effects. For ex- 
ample, mycophenolic acid (MPA) has been widely used as  
an immunosuppressive drug after transplantation [38].  
MPA-induced beta-cell toxicity is an important factor for  
islet graft function. The signal transduction mechanism un- 
derlying this process has not been fully explored. Using a  
proteomics approach, Park et al. [39] examined protein ex- 
pression patterns in MPA-treated apoptotic RIN-5 cells and  
found a decrease in the expression of RhoGDI-alpha.  
Over-expression of RhoGDI-alpha increased cell viability  
and decreased activated JNK expression following exposure  
to MPA, whereas knockdown of RhoGDI-alpha enhanced  
MPA-induced cell death and increased the activation of  
JNK. MPA-induced cell death was prevented by a JNK in- 
hibitor. The proteomic analysis indicated that MPA induces  
significant apoptosis in insulin-secreting cells via the down- 
regulation of RhoGDI-alpha linked with increased JNK  
expression. This RhoGDI-alpha/JNK pathway might be the  
focus of therapeutic target for the prevention of MPA-in- 
duced islet apoptosis.  
Pollutants in the environment have increased in the past  
years, coincident with economic development. Some envi- 
ronmental contaminants demonstrated toxicity on organisms  
via apoptosis induction. Proteomic analysis of these com- 
pounds could provide useful information for human health  
protection. The environmental contaminant 2,3,7,8-tetra-  
chlorodibenzo-p-dioxin (TCDD) has been shown to cause a  
wide variety of toxic effects and is regarded as the most  
potent hepatocarcinogen in experimental animals [40]. For a  
comprehensive survey of the impact of TCDD on the pro- 
teome of hepatic cells, Sarioglu et al. [41] performed a high  
resolution 2D gel electrophoresis study on the rat hepatoma  
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cell line 5L exposed to TCDD. A particularly intriguing  
finding was that the upregulation of the mitochondrial outer  
membrane pore protein, voltage-dependent anion channel- 
selective protein 2 (VDAC2), depended on the presence of a  
functional aryl hydrocarbon receptor. In view of the central  
role of VDAC2 as an inhibitor of the activation of the  
proapoptotic protein BAK, and the mitochondrial apoptotic  
pathway, their data point to a hitherto unrecognized mecha- 
nism by which TCDD might affect cellular homeostasis and  
survival. Another example is 1,2-dichlorovinyl-L-cysteine  
(DCVC), which belongs to the group of nephrotoxic halo- 
genated alkene S-cysteine conjugates and is specifically  
taken up by renal proximal tubular cells both in vitro and in  
vivo where it is bio-activated by the renal cysteine conju- 
gate-lyase activity, resulting in the formation of reactive  
intermediates that cause cell injury [42]. De Graauw et al. [43]  
used 2D-DIGE to determine early changes in the onset  
of apoptosis of renal epithelial cells induced by DCVC.  
They identified a significant change in HSP27, which dem- 
onstrated a pI shift in association with an altered phospho- 
rylation status. They also found that the inhibition of p38 by  
SB203580 reduced HSP27 phosphorylation and accelerated  
reorganization of focal adhesions, cell detachment, and  
apoptosis. Overexpression of a phosphorylation-defective  
mutant HSP27 had a dominant-negative effect and acceler- 
ated the DCVC-induced changes in focal adhesions as well  
as the onset of apoptosis. Their proteomic analysis indicated  
that phosphorylation of HSP27 via p38 activation might be a  
possible means to maintain cell adhesion, and thus suppress  
renal epithelial cell apoptosis by DCVC. 
While some small molecular compounds may not be drug  
leads, they might have special activities in biological sys- 
tems that could lead to the discovery of unknown mecha- 
nisms and pathways involved in these complex biological  
processes. For example, apoptosis triggered by endoplasmic  
reticulum (ER) stress has been implicated in many diseases,  
but its cellular regulation remains poorly understood [44].  
Salubrinal is a small molecule that protects cells from ER  
stress-induced apoptosis by selectively activating a subset of  
endogenous ER stress-signaling events [45]. Boyce et al. [46] 
used salubrinal as a probe in a DIGE-based proteomic 
approach to discover new information about the endogenous  
cellular response to ER stress. They found that one set of  
protein spots shifted toward the anode of the IEF dimension  
in response to salubrinal treatment. These spots were identi- 
fied as eEF-2 by mass spectrometry. A shift toward the an- 
ode in the IEF dimension is consistent with a phosphoryla- 
tion event and they subsequently identified the phosphory- 
lation site (residues 55–59 of rat eEF-2). Using this infor- 
mation, they tracked the upstream protein kinase event and  
identified eEF-2K as a hitherto unknown regulator of ER  
stress-induced apoptosis.  
We found that a new camptothecine derivate, NSC606985,  
could induce AML cell apoptosis via proteolytic activation of  
protein kinase delta (PKCδ) at nanomole concentrations [47].  
NSC606985 also demonstrated therapeutic effects on  
an AML leukemic mouse [48]. We then performed dynamic  
proteomic analysis of leukemic NB4 cells with NSC606985  
as an apoptosis-inducing probe and identified a large set of  
proteins that were deregulated in apoptosis [18]. In combi- 
nation with bioinformatics, a hypothetical network of these  
deregulated proteins was constructed and provided clues to  
new apoptosis mechanisms [27]. Based on these clues, we  
found that the acidic leucine-rich nuclear phosphoprotein  
32B (ANP32B) was a substrate of caspase-3 and that the  
knocking down of ANP32B sensitized the cells to apoptotic  
stimuli [49]. More intriguingly, further analysis showed that  
the ANP32B caspase-3 cleavage fragment might have im- 
portant roles in apoptotic regulation (data not shown). In  
addition, hnRNPK was also found to decrease via protea- 
some degradation during apoptosis, and its knockdown also  
contributed to apoptosis induction [50]. In addition, we  
found that dihydrofolate reductase (DHFR) is translocated  
from the cytosol to the nucleus during the apoptosis [51].  
Recent data from our laboratory supported the view that this  
translocation was required for apoptosis induction under  
certain conditions such as ER stress. Among these findings,  
most of the protein deregulations occurred later in apoptosis.  
With the advantage of easy control of apoptosis induction  
via dosage and time modification for chemical compound  
treatment, we found that the expression of N-myc down- 
stream-regulated gene 1 (NDRG1) decreased prior to the  
cleavage of PKCδ in apoptosis induced by NSC606985. In  
addition, NDRG1 downregulation was found to sensitize the  
leukemic cells to apoptosis induction by promoting the pro- 
teolytic activation of PKCδ [52].  
2  Tumor suppressors and oncogenes 
The apoptosis process is finely regulated by a series of  
modulators. For example, tumor suppressors, such as wild- 
type p53 and Bax, and oncogenes such as mutant P53, Bcl-2,  
and bcl-XL have been proposed to have crucial roles in  
modifying the susceptibility of normal and cancer cells to  
the induction of apoptosis [26,53]. Research into the modu- 
lation of apoptosis-regulating genes has thus evoked great  
interest and proteomics has been frequently used as an ef- 
fective research strategy.   
Proapoptotic B-cell lymphoma-2 (Bcl-2) family members  
are the requisite arbiters of the mitochondrial apoptotic  
pathway [54]. The Bcl-2 family is conserved through evolu- 
tion and consists of both proapoptotic and anti-apoptotic  
members. The Bcl-2 family is divided into three sub-groups.  
The first group includes the pro-apoptotic members BAX  
and BAK, which constitute a requisite gateway to the mito- 
chondrial pathway of apoptosis, and their allosteric activa- 
tion results in the permeabilization of the outer mitochon- 
drial membrane and the release of cytochrome C. The sec- 
ond group is the BH3-only molecules, including BAD, BID,  
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and others, which can result in the activation of BAX and  
BAK or can be sequestered by the anti-apoptotic Bcl-2 and  
Bcl-XL. The third group is Bcl-2, Bcl-XL, and other  
anti-apoptotic members in the family. The fine balance be- 
tween the expression levels of pro- versus antiapoptotic  
Bcl-2 family members, as well as interactions among them,  
determines whether the cell lives or dies, and this process is  
regulated at the transcriptional or post-translational level.  
However, the detailed mechanisms of the interactions of  
Bcl-2 family and the activation of BAX and BAK are still  
not clear, and constitute the Holy Grail of apoptosis re- 
search [9]. To purify the interacting proteins of BAX, Kerr  
et al. [55] used the native 21 amino-acid C terminus of Bax,  
which does not result in mitochondrial translocation on its  
own, and its S184V mutant peptide, which artificially mim- 
ics the correct conformation for targeting Bax to the mito- 
chondria. Using columns of biotinylated peptides coupled to  
agarose beads, affinity chromatography was performed us- 
ing SH-SY5Y cell lysates and bound proteins were sepa- 
rated by SDS-PAGE followed by mass spectrometry identi- 
fication. They found that the molecular chaperone nucleo- 
phosmin was a novel Bax-binding protein. Specific RNAi- 
mediated knockdown of nucleophosmin expression attenu- 
ated apoptosis. Thus, they elucidated a novel molecular  
mechanism whereby Bax becomes activated and translo- 
cates to the mitochondria to orchestrate mitochondrial dys- 
function and apoptotic cell death. On the other hand, an- 
other proteomic investigation found that Bax could also be  
transcriptionally regulated by knocking down CTCF, which  
is highly expressed in breast cancer cell lines and tumors  
compared with breast cell lines with finite life span and  
normal breast tissues. This analysis supports the hypothesis  
that the upregulation of CTCF might be linked to the resis- 
tance of breast cancer cells to apoptosis [56]. Notably, BAK  
and BAX are usually thought to act as requisite arbiters of  
mitochondria. However, Hwang et al. [57] used a SILAC  
(stable isotope labeling by amino acids in cell culture)- 
based unbiased quantitative proteomic analysis of nuclear  
fraction of Jurkat cells during apoptosis induced by anti-Fas  
antibody and found that the mitochondrial protein BAK was  
dynamically recruited into nuclear invaginations during  
apoptosis. This might indicate that BAK has roles in the  
nucleus other than its known roles in mitochondria. In a gel  
filtration chromatography-based proteomic analysis, Danial  
et al. [58] found that the BH-3-only pro-apoptotic BAD  
resides in a functional holoenzyme complex together with  
glucokinase and is required to assemble the complex in liver  
mitochondria. Notably, in BAD-deficient hepatocytes that  
lack this complex, mitochondria-based glucokinase activity,  
and mitochondrial respiration in response to glucose, di- 
minished. Glucose deprivation results in dephosphorylation  
and activation of BAD, and induces BAD-dependent cell  
death. This proteomics-based protein complex analysis in- 
dicates an unanticipated role for BAD in integrating path- 
ways of glucose metabolism and apoptosis. Liu et al. [59]  
identified JAB1 as a novel BclGs-specific binding protein  
through a yeast two-hybrid screening in a human testis  
cDNA library. The N-terminal region of BclGs was required  
for the interaction. JAB1 could compete with Bcl-XL/Bcl-2 to  
bind to BclGs and thus promote apoptosis. Cimmino et al. [60]  
found that cells overexpressing “wild-type” human  
isoaspartyl protein carboxyl-O-methyltransferase (PCMT)  
were resistant to apoptosis, whereas overexpression of an- 
tisense PCMT induced high sensitivity to apoptosis, even at  
low H2O2 concentrations. By incubating the purified human  
recombinant PCMT with cell lysate, they identified that  
Bcl-xL was a specific methyl-accepting substrate of PCMT  
and thus lost its anti-apoptotic activity for the methylation  
modification. In a quantitative proteomic analysis for  
Myc-induced apoptosis using an isotope-coded affinity tag,  
the expression of Bcl-2 and Bcl-xL was found to be sup- 
pressed, which indicated that the increase of Bcl-2 and  
Bcl-xL in tumor cells might be one of the means to escape  
Myc-induced apoptosis [61]. These proteomics analyses  
provided valuable information on the molecular mecha- 
nisms of Bcl-2 family in apoptosis regulation. 
As an important tumor suppressor protein, p53 is often  
referred to as the “guardian of the genome” [53]. p53 re- 
sponds to DNA-damage or checkpoint failure and gives rise  
to a series of anti-proliferative responses, including apop- 
tosis induction through transcription dependent or inde- 
pendent mechanisms, while disruption of this route can  
promote tumor progression and chemoresistance. For ex- 
ample, approximately 50% of sporadic human tumors har- 
bor somatic mutations in the p53 gene locus. Therefore, to  
ensure normal cell growth, p53 levels and activity are  
tightly regulated. Post-translational modification following  
exposure to a variety of stresses is one of the major phe- 
nomena of p53. However, there have been conflicting re- 
ports on whether p53 post-translational modifications, such  
as phosphorylation or acetylation, are essential or only play  
a subtle, fine-tuning role in the p53 response. In a cleavable  
ICAT quantitative proteomics analysis of thymocytes from  
p53(K317R) knock-in mice treated by ionizing radiation, 46  
proteins were found to be differentially affected [62]. Path- 
way analysis of these proteins suggested an increase in p53  
activity in the p53(K317R) thymocytes as well as a decrease  
in tumor necrosis factor alpha signaling. These results sug- 
gest that the acetylation of Lys-317 modulates the functions  
of p53 and influences the cross-talk between the DNA  
damage response and other signaling pathways [62]. A  
milestone work was recently reported by Tang et al. [63].  
They identified all major acetylation sites of p53 based on a  
proteomic analysis. They also found that the loss of acetyla- 
tion completely abolished p53-dependent growth arrest and  
apoptosis. Acetylation of p53 abrogated Mdm2-mediated  
repression by blocking the recruitment of Mdm2 to p53- 
responsive promoters, which leads to p53 activation inde- 
pendent of its phosphorylation status. This study demon- 
strated p53 acetylation as an indispensable event for desta- 
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bilizing the p53-Mdm2 interaction and enabling the  
p53-mediated stress response. 
The tumor suppressor p53 executes its function partially  
by transcriptional regulation of a set of target genes. Clearly,  
identification of new p53 targets is important to achieve a  
better understanding of the p53 tumor suppressor pathway.  
Gu et al. [64] compared the proteome of a human colorectal  
cancer cell DLD-1 transfected with inducible p53 with that  
of the control cell line using amino acid-coded mass tag- 
ging-assisted mass spectrometry. They identified a large  
dataset of proteins that are upregulated at the execution  
stage of p53-mediated apoptosis. Meanwhile, using ICAT  
labeling and high throughput mass spectrometry, Johnson et  
al. [65] identified in vivo quantitative changes in wild-type  
p53 mouse cortical neurons undergoing camptothecine  
DNA damage-induced death and found a large set of  
changed proteins. Using a 2DE-based quantitative proteo- 
mic method, Rahman-Roblick et al. [66] compared the total  
proteins from MMC-treated p53+/+ or p53−/− HCT116  
cells and found many deregulated proteins. In addition to  
transcriptional regulation, it is conceivable that p53 regu- 
lates targets at the post-translational level. In fact, Rahman- 
Roblick et al. [66] demonstrated that both transcription- 
dependent and transcription-independent regulation were  
among the identified targets in a previous study. Further- 
more, Rahman-Roblick et al. [67] examined p53-dependent  
phosphorylation using 2DE and staining with the fluores- 
cent phosphoprotein dye Pro-Q Diamond and reported a sub- 
set of putative protein phosphorylation events. Orre et al. [68] 
showed that the phosphorylation of S100A6 is depen- 
dent on p53 using SELDI-TOF based top-down mass spec- 
trometry. Thus, proteomic analysis could increase the un- 
derstanding of the mechanisms of p53 regulation and bio- 
logical function, which then provide the basis for new drug  
designs that could eventually lead to therapeutics to reacti- 
vate p53 in cancers. 
The transmission of apoptotic signals from the plasma  
membrane to the nucleus involves a number of different  
pathways and protein modifications, primarily in the form  
of phosphorylation, which lead to the activation of a series  
of protein kinases. Activation of specific protein kinases can  
promote cell death in some circumstances, while others  
protect the cell against apoptosis [69]. Thus, the discovery  
of protein kinase substrates would achieve a better under- 
standing of apoptotic signaling. Protein-protein interactions  
between kinases and substrates are required for the phos- 
phorylation reaction and thus protein-protein interaction  
studies are an effective strategy to identify the substrates as  
well as the regulators of the kinases. For example, Galietta  
et al. [70] identified several RNA/DNA-binding proteins,  
including protein-associated splicing factor (PSF), that  
coimmunoprecipitated with NPM/ALK. PSF was revealed  
as a substrate of ALK by further analysis, and ALK fusion  
proteins could induce phosphorylation and delocalization of  
PSF from the nucleus to the cytoplasm in NPM/ALK(+)  
cells. PSF phosphorylation decreased the PSF-mediated  
suppression of GAGE6 expression and possibly contributed  
to the pathogenesis of lymphoma. In an unbiased proteomic  
screening using yeast two-hybrid assays to identify integrin- 
linked kinase (ILK) interactors, rictor was revealed as an  
ILK-binding protein. Single depletion of rictor decreased  
ILK-related Akt Ser (473) phosphorylation and depletion of  
ILK and rictor in breast and prostate cancer cell lines re- 
sulted in the inhibition of Akt Ser (473) phosphorylation  
and induction of apoptosis. These data show that rictor  
regulates the ability of ILK to promote Akt phosphorylation  
and cancer cell survival [71]. With the development of  
strategies and technologies for the enrichment of phospho- 
rylated protein/peptides and the improvement in sensitivity  
and throughput of MS analysis, phosphorylation profiling  
analysis has become an alternative option to identify the  
protein substrates of kinases. To better understand the  
signaling properties of oncogenic FGFR3, Kang et al. [72]  
performed phospho-proteomic studies and identified many  
potential downstream signaling effectors that are tyrosine  
phosphorylated in hematopoietic cells expressing constituti- 
vely activated leukemogenic FGFR3 mutants. Furthermore,  
they found that FGFR3 directly phosphorylates the serine/ 
threonine kinase p90RSK2 at Y529. This phosphorylation  
consequently regulates RSK2 activation by facilitating  
inactive ERK binding to RSK2, which is required for  
ERK-dependent phosphorylation and activation of RSK2,  
which, in turn, mediates hematopoietic transformation. 
Intriguingly, some canonical kinases might have an im- 
portant role via kinase-independent pathways. For example,  
the serine/threonine kinase Raf acts as an important factor  
in the ras pathway [73], but some studies found that ablation  
of the Raf-1 gene causes widespread apoptosis and embry- 
onic lethality, despite normal regulation of ERK through  
B-Raf [74]. Similarly, Raf-1 deficient fibroblasts are hyper- 
sensitive to apoptosis that is induced by selected stimuli,  
including serum withdrawal and stimulation of the death  
receptor Fas. Knock-in of Raf-1 in a Raf-1 mutant that can- 
not be activated fully rescued the phenotype. The ablation  
of the protein kinase Raf-1 renders cells hypersensitive to  
apoptosis, despite normal regulation of extracellular signal- 
regulated kinases, suggesting that apoptosis protection is  
mediated by an unknown pathway. To search for new  
partners in Raf-1 signaling, O’Neill et al. [75] immunopuri- 
fied proteins associated with flag-tagged Raf-1 that were  
expressed in COS-1 cells, and identified that Raf-1 coun- 
teracts apoptosis by suppressing the activation of mammal- 
ian sterile 20-like kinase (MST2). Raf-1 prevents dimeriza- 
tion and phosphorylation of the activation loop of MST2  
independently of its protein kinase activity. Depletion of  
Raf-1 from mouse or human cells led to MST2 activation  
and apoptosis. Depletion of MST2 from Raf-1−/− mouse or  
human cells abrogated sensitivity to apoptosis, whereas  
overexpression of MST2 induced apoptosis. Furthermore,  
they immunoprecipitated MST2 and identified LATS1 as a  
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MST2 binding partner. They found that the tumor suppres- 
sor gene RASSF1A disrupted the inhibitory Raf1-MST2  
complex and enhanced the MST2 interaction with its sub- 
strate, LATS1. Subsequently, RASSF1A-activated LATS1  
phosphorylates and releases the transcriptional regulator  
YAP1, allowing YAP1 to translocate to the nucleus and as- 
sociate with p73, resulting in transcription of the proapoptotic  
target gene, puma [76]. 
3  Caspases and other protease substrates 
Since human caspase-1 was identified as the C. elegans  
homolog of CED-3, the caspase family has been the subject  
of intense research because of their distinct physiological  
functions, substrates, activation mechanisms, and signal  
transduction pathways. This research has made a large con- 
tribution to the understanding of the molecular mechanisms  
of apoptosis as well as demonstrating the involvement of  
caspases in the pathogenesis of certain diseases [7,24]. No- 
tably, as aspartic acid-specific proteases, caspases have cru- 
cial roles in apoptosis via specific proteolytic cleavage of  
protein substrates. It is probable that the cleavage of some  
of these substrate proteins simply represent “innocent by- 
standers” that are degraded following the death program.  
However, a few of these protein cleavages, such as caspases,  
RB, IAP, and PARP, have been rigorously established as  
biologically relevant steps in protein activation and translo- 
cation, and have important function in the signature events  
in apoptosis, such as membrane phosphatidylserine exter- 
nalization, cellular retraction, chromatin condensation, and  
apoptotic body production [77]. In fact, in our laboratory,  
we have identified that the leukemic fusion protein AML-  
ETO, and ANP32B, are substrates of caspase-3 and their  
products play important roles in apoptosis regulation [78].  
In addition, substrate identification aids in revealing en- 
zymatic functions. For example, members of the caspase  
family of proteases have crucial roles in coordinating apop- 
totic events and it was assumed that the major executioner  
caspases, caspase-3 and caspase-7, exhibit functionally re- 
dundant roles within the cell death machinery because they  
show similar activity toward certain synthetic peptide sub- 
strates [79]. However, the distinct phenotypes of mice de- 
ficient in these caspases make this assumption controver- 
sial [80]. Using cell-free caspase-3-depleted Jurkat ex- 
tracts and 2DE analysis, Walsh et al. [81] showed that cas- 
pase-3 and caspase-7 exhibit differential activity toward  
multiple substrate proteins. The removal of caspase-3 abol- 
ished the vast majority of caspase-dependent proteolytic  
changes evident in this system, with few proteins undergo- 
ing proteolysis in the caspase-3-depeleted extract. This  
suggested that caspase-3 is more promiscuous than caspase- 
7 and appears to be the major executioner caspase during  
the demolition phase of apoptosis. Thus, the recognition of  
caspase substrates during the demolition phase of apoptosis  
was one of the focuses of apoptosis research. In the past  
decade, the list of proteins that are reported to be cleaved by  
caspases in vivo and in vitro has grown rapidly and several  
hundred substrates of apoptosis-associated caspases have  
been reported [77,82–84]. These substrates usually share  
relatively common sequences (for example, tetrapeptide  
sites after a highly conserved aspartic acid residue) within  
proteins and it was thought that there are likely to be  
hundreds more intracellular proteins yet to be discovered  
that match the consensus substrate specificity of caspases.  
For example, bioinformatics has been applied to predict  
substrates in the genome and has provided many putative  
substrates and cleavage sites [85]. However, these putative  
substrates remain to be experimentally verified. Therefore,  
there is considerable interest in the development of method- 
ologies that would allow for a comprehensive characteriza- 
tion of the proteolytic pathways in apoptotic systems. Inno- 
vative proteomics-based methods and high-throughput pro- 
tein separation and identification have significantly influ- 
enced the search for caspase substrates on a global scale.  
Dix et al. [86] set up a robust and conventional gel-based  
proteomic platform that enabled direct visualization of the  
topography and magnitude of proteolytic events on a global  
scale. Protein samples were extracted from control native and  
apoptotic cells and separated by SDS-PAGE. Full-length  
proteins will be present in the control native lane while the  
fragments of the native proteins after cleavage will be present  
in the apoptotic cell lane with a lower molecular weight. To  
identify the proteins, the SDS-PAGE gel was sliced into  
strips, followed by trypsin digestion and LC-MS/MS analy- 
sis. The presence of the same peptides at different molecular  
weights thus provided information about the identity of the  
cleaved proteins. They identified 91 characterized caspase  
substrates as well as 170 additional proteins previously not  
known to be cleaved during apoptosis. Surprisingly, they  
found that the vast majority of proteolyzed proteins, regard- 
less of the extent of cleavage, yielded persistent fragments  
that corresponded to discrete protein domains, which sug- 
gested that the generation of active effector proteins might  
be a principal function of apoptotic proteolytic cascades [86].  
Mahrus et al. [87] presented an intriguing approach to  
the problem of how to specifically label the N termini of  
proteins to allow for the enrichment of corresponding  
N-terminal peptides and identification of the locations of  
protease cleavage sites. They used subtiligase to tag free N  
termini with a biotin peptide after apoptosis induction, fo- 
llowed by LC-MS/MS analysis and database searching. They  
have sequenced 333 caspase-like cleavage sites distributed  
among 292 protein substrates. They also found that caspase  
cleavage sites often appear in surface-accessible loops, and  
a disproportionate number of caspase substrates physically  
interact, suggesting that these dimeric proteases target  
protein complexes and networks to elicit apoptosis. With  
the rapid advance of quantitative proteomic technology,  
including the SILAC and iTRAQ (isobaric tag for relative  
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and absolute quantitation) [88], more and more powerful  
methods could be developed and applied to discover more  
novel caspase substrates and cleavage sites. Accordingly,  
the proteins cleaved by caspases will form an even longer  
list. It is necessary to summarize these proteins as a data- 
base and even identify the subset of these proteins that have  
functional significance for the process of apoptosis and/or  
inflammation. Luthi et al. have compiled a comprehensive  
list of caspase substrates (The Casbah; www.casbah.ie),  
which contains information pertaining to most of the cur- 
rently known caspase substrates [83]. 
It has been long supposed that several other proteases are  
engaged in cleavage activity during the apoptotic process,  
which has been demonstrated by several investigations, in- 
cluding proteomic efforts. Van et al. [89] used fractional  
diagonal chromatography sorting of protein amino-terminal  
peptides coupled to oxygen-16 or oxygen-18 differential  
labeling to discover the protein cleavage in anti-Fas-treated  
apoptotic human Jurkat T lymphocytes. They located 93  
cleavage sites in 71 proteins in anti-Fas-treated apoptotic  
human Jurkat T lymphocytes. As expected, most cleavages  
were at caspase consensus sites. However, 35 other cleav- 
ages occurred C-terminally to nonaspartate residues, mainly  
involving either basic or bulky hydrophobic amino acids,  
suggesting activation of other proteases. Similarly, Impens  
et al. [90] analyzed the involvement of proteases during  
taxol-mediated cell death of human A549 non-small-cell  
lung carcinoma cells using a proteomic approach. They re- 
vealed 27 protease-mediated cleavages, which included  
cleavage sites C-terminal to aspartic acid and sites C-terminal  
to non-Asp residues, as the result of caspase and non-cas- 
pase protease activities, respectively. 
Among these non-caspase proteases involved in apop- 
totic process, Granzyme B, a major cytotoxic T lympho- 
cyte/natural killer (CTL/NK) granule protease, was the most  
widely investigated [13]. Granzyme B was known to acti- 
vate members of the caspase family of cysteine proteases  
through processing of caspase zymogens, and can thus initi- 
ate apoptosis under certain stimuli [14]. However, it is sup- 
posed that more proteins could be the potential substrate of  
Granzyme B during apoptosis. To identify the specific pro- 
tein substrates from the huge number of cleavages in the  
apoptotic products, Bredemeyer et al. [91] treated YAC-1  
cells with granzyme B in the presence of caspase inhibitors  
and used DIGE (differential gel electrophoresis) and tandem  
MS to identify substrates of granzyme B. They found pro- 
caspase-3 and several other substrates of granzyme B. Al- 
ternatively, Adrain et al. [92] used a cell-free system and a  
2DE-based proteomics approach to investigate molecular  
order and relative importance of caspase activation events  
that occur in target cells during granzyme B-initiated apop- 
tosis. They examined the scale of granzyme B-initiated al- 
terations to the proteome in the presence or absence of ef- 
fector caspase-3 or -7. Their study indicated that granzyme  
B targets a highly restricted range of substrates and orches- 
trates cellular demolition largely through activation of cas- 
pase-3. 
The mitochondrial serine protease high-temperature re- 
quirement protein A2 (HtrA2/Omi) is expressed from a nu- 
clear gene as a proenzyme of 49 kD with an N-terminal  
mitochondrial localization signal that mediates its transloca- 
tion into the mitochondrial intermembrane space. HtrA2/ 
Omi is one of the factors that are released into the cytosol  
after apoptotic stimuli [93]. The proteolytic activity of  
HtrA2/Omi was found to have an important role in caspase- 
dependent apoptosis and, more importantly, it is also  
required in a caspase-independent manner. However, except  
for IAP [94], very few targets of HtrA2/Omi were known.  
To identify apoptotic targets of HtrA2/Omi, Vande Walle et  
al. [95] purified recombinant HtrA2/Omi and its catalyti- 
cally inactive S306A mutant. Lysates of human Jurkat T  
lymphocytes incubated with either wild-type recombinant  
HtrA2/Omi or the S306A mutant and subjected to mass  
spectrometry identification yielded 15 HtrA2/Omi sub- 
strates and 50 cleavage sites of potential physiological rele- 
vance. Several processing events were validated by incu- 
bating purified recombinant HtrA2/Omi with in vitro trans- 
lated substrates or with Jurkat cell lysates. In addition, the  
set of cleavage sites was used to assess the protein substrate  
specificity of HtrA2/Omi. The results suggest that  
HtrA2/Omi has a rather narrow cleavage site preference and  
that cytoskeletal proteins are the prime targets of this prote- 
ase. 
4  Summary 
This review summarizes the major advances in functional  
proteomics and chemical/drug proteomics in apoptosis re- 
search. With throughput and sensitivity that are unparalleled  
by traditional biochemical methods, proteomic strategies  
and technologies have demonstrated particular advantages  
in substrate identification for proteases and protein kinases  
which are critical for apoptosis and for other biological  
processes such as inflammation. Sensitivity and throughput  
are still being improved to accommodate the highly de- 
manding nature of genome-wide identification of proteins.  
At present, only highly abundant proteins can be identified  
in whole cells or tissue lysate, and various protein isolation  
and purification strategies are needed to identify certain  
groups of proteins.  
With the length limitation of this review, much interest- 
ing work was not included. For example, for the proteomic  
analysis of post-translational modifications in apoptosis  
research, we focused on phosphorylation because of its long  
research history and relatively mature technologies. Much  
excellent work will emerge as a result of the fast develop- 
ment of other PTM proteomic technologies, such as acetyla- 
tion, SUMOylation, ubiquitination, glycosylation, and me- 
thylation. Furthermore, new technologies that investigate  
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protein-protein interactions, small compound-protein inter- 
actions, and protein-DNA/RNA interactions will reveal  
even more important apoptosis regulators and mechanisms. 
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